Navigation Links
Liver Diseases: A Huge European Health Burden, But Some Trends are Positive
Date:4/23/2008

on. When uncontrollable complications of cirrhosis occur, or when damage precludes sufficient liver function, a liver transplant becomes necessary. Cirrhosis is the major risk factor for the development of hepatocellular carcinoma (HCC), a primary cancer of liver cells, which may also require transplantation.

Estimates suggest 10 million carriers of viral hepatitis in Europe, of which over 8 million are infected with HCV. Although statistics vary widely by country, HCV accounts for a large (or in some countries, majority) proportion of all cases of cirrhosis and HCC. Although precise figures are not available, alcoholic liver disease is a growing problem in both Western and Eastern Europe, in part because of changing lifestyles and the increasing numbers of women and adolescents who drink to excess (a problem that in the past was largely a phenomenon of adult males). The Dionysos study, conducted in Northern Italy, reported that 4% of the population had alcoholic liver disease of varying severity. Alcoholic liver disease is the second most common indication for liver transplantation, after HCV. NAFLD and NASH denote fatty infiltration of the liver that are not due to excessive alcohol, and are related instead to insulin resistance, type 2 diabetes, obesity, and the metabolic syndrome. These abnormalities are now receiving considerable attention not only because they may progress to liver cirrhosis, but also as additional risk factors for cardiovascular disease. The best current estimates suggest that in the general population NAFLD can be found in 3% to 24% of adults.

Despite improved prevention, diagnosis, and treatment, the overall costs of liver disease remain very high because of an increase prevalence of selected conditions, and the common progression to a chronic state possibly leading to life-threatening complications.

About EASL

The European Association for the Study of the Liver (EASL) aims to promote investigation into liver dis
'/>"/>

SOURCE EASL - European Association for the Study of the Liver
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Susan G. Komen for the Cure(R) Announces Largest Grants Slate Ever: $100 Million to Speed Delivery of Breast Cancer Discoveries, Cures
2. Another industry first enabled by Benchmark Biolabs - Peros oral delivery platform and vaccine facility licensed by the USDA
3. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
4. Method to deliver molecules within embryonic stem cells improves differentiation
5. Genetic Engineering and Biotechnology News (GEN) Presents Exclusive Podcast with Robert Langer, Ph.D. on New Polymeric Drug Delivery Systems
6. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
7. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
8. Patient Experience Expert to Present The Power of Wow! in Health Care Service Delivery
9. Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
10. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
11. Minimally Invasive Treatment Offers Hope for Liver Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 Celsion Corporation (the "Company") (NASDAQ: ... from two institutional healthcare investors to purchase an aggregate ... in an at-the-market registered direct offering and a concurrent ... The Company entered into a definitive purchase agreement ... to sell an aggregate of 3,000,000 shares of its ...
(Date:5/28/2015)... 28, 2015 BioNorth Texas (BioNorthTX), ... representing the life sciences industry in northern region ... meeting at The Foundry in Dallas on April ... brought together a broad spectrum of biotech professionals ... organization's early successes in partnering with key life ...
(Date:5/28/2015)... , May 28, 2015 Biscayne ... anti-cancer potential of its growth hormone-releasing hormone (GHRH) technology ... the 2015 ASCO Annual Meeting. The data show that ... Biscayne,s anti-cancer GHRH blockers, is present on many primary ... findings suggest that GHRH antagonists could have broad anti-cancer ...
(Date:5/28/2015)... The Fertility Centers of New England is proud ... taken on a new and expanded role as Medical ... leadership, oversight and quality assurance for the practice. , ... team of experienced reproductive endocrinologists,” said Fertility Centers of ... “Her expertise and compassionate, individualized care have helped set ...
Breaking Biology Technology:Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
... 24, 2011 Ventana Medical Systems, Inc. (Ventana), a ... the U.S. Food and Drug Administration (FDA) for the ... with associated VIRTUOSO software and iScan Coreo Au scanner. ... workflow solution for determining HER2 (4B5) expression in breast ...
... BEIJING, Oct. 24, 2011 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, ... of the leading plasma-based biopharmaceutical companies in the People,s ... included in Forbes Magazine,s annual list of Asia,s "200 ... Company was also named to the same list for ...
... LONDON, October 24, 2011 Silence ... interference (RNAi) therapeutics company, today announced that it ... Inc. ("Mirna"), a biopharmaceutical company pioneering microRNA-based therapeutics ... Silence,s proprietary AtuPLEX™ and DBTC delivery systems for ...
Cached Biology Technology:Ventana Receives FDA Clearance for HER2 (4B5) Image Analysis and Digital Read Applications 2China Biologic Named to Asia's "200 Best Under a Billion" by Forbes Asia 2China Biologic Named to Asia's "200 Best Under a Billion" by Forbes Asia 3Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics 2Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics 3Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics 4Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics 5Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics 6
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
(Date:5/19/2015)... 19, 2015 Research ... addition of the  "Genetic Testing Market Outlook ... http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic Testing ... of the current and future genetic testing ... their working principles and types are covered ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated ... human interface solutions, today announced the appointment of ... and Chief Financial Officer, reporting to Rick ... Synaptics, current Chief Financial Officer, Kathleen Bayless ... Mr. Ali brings extensive financial ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... A University of Minnesota research team featuring researchers from the ... Drug Design has developed a new delivery system for a ... an effective treatment for the human immunodeficiency virus (HIV). ... decitabine and gemcitabine to be delivered in pill form, marks ...
... WASHINGTONA George Washington University researcher will receive $1.3 million ... of Diabetes and Digestive and Kidney Diseases (NIDDK) for ... diabetes develops, possibly informing the development of novel treatments ... important given 150 million people worldwide suffer from type ...
... regularly, but still aren,t seeing improvements in your health, there ... report published in the September issue of The ... may not be the problem, but what,s in what you ... evidences for rethinking the way of addressing risk assessment especially ...
Cached Biology News:Drug design success propels efforts to fight HIV with a combination of 2 FDA-approved drugs 2Type 2 diabetes study to examine role amylin plays in disease 2'Safe' levels of environmental pollution may have long-term health consequences 2
... a complete assay system for the measurement ... serum or plasma. The assay incorporates the ... IDS 1,25D RIA followed by quantitation by ... to use reagents, no organic or solvent ...
Rabbit polyclonal to Nck alpha ( Abpromise for all tested applications). entrezGeneID: 4690 SwissProtID: P16333...
anti-achaete...
ATP-binding cassette sub-family D member 4 (Peroxisomal membrane protein 69) (PMP69) (Peroxisomal membrane protein 1-like) (PXMP1-L) (P70R). [Source:Uniprot/SWISSPROT;Acc:O14678] Antigen: Recombi...
Biology Products: